HILS vs. VIRI, WHWK, OSTX, PYRGF, ATNM, ELYM, NBRV, AADI, EGRX, and NNVC
Should you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), PyroGenesis Canada (PYRGF), Actinium Pharmaceuticals (ATNM), Eliem Therapeutics (ELYM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), and NanoViricides (NNVC).
Hillstream BioPharma vs. Its Competitors
Virios Therapeutics (NASDAQ:VIRI) and Hillstream BioPharma (NASDAQ:HILS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.
Virios Therapeutics is trading at a lower price-to-earnings ratio than Hillstream BioPharma, indicating that it is currently the more affordable of the two stocks.
Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Hillstream BioPharma has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500.
Virios Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 1.63%. Given Virios Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Virios Therapeutics is more favorable than Hillstream BioPharma.
Virios Therapeutics' return on equity of -130.33% beat Hillstream BioPharma's return on equity.
In the previous week, Virios Therapeutics had 1 more articles in the media than Hillstream BioPharma. MarketBeat recorded 1 mentions for Virios Therapeutics and 0 mentions for Hillstream BioPharma. Virios Therapeutics' average media sentiment score of 0.00 equaled Hillstream BioPharma'saverage media sentiment score.
9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 13.4% of Hillstream BioPharma shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 30.2% of Hillstream BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Virios Therapeutics beats Hillstream BioPharma on 7 of the 11 factors compared between the two stocks.
Get Hillstream BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HILS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hillstream BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:HILS) was last updated on 8/16/2025 by MarketBeat.com Staff
MarketBeat All Access